- Home
- EPRX vs RGLS Comparison
EPRX vs RGLS Comparison
Compare EPRX & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- RGLS
- Stock Information
- Founded
- EPRX 2011
- RGLS 2007
- Country
- EPRX Canada
- RGLS United States
- Employees
- EPRX N/A
- RGLS N/A
- Industry
- EPRX
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- EPRX
- RGLS Health Care
- Exchange
- EPRX NYSE
- RGLS Nasdaq
- Market Cap
- EPRX 111.1M
- RGLS 102.1M
- IPO Year
- EPRX N/A
- RGLS 2012
- Fundamental
- Price
- EPRX $3.33
- RGLS $1.60
- Analyst Decision
- EPRX Strong Buy
- RGLS Strong Buy
- Analyst Count
- EPRX 1
- RGLS 6
- Target Price
- EPRX $9.00
- RGLS $10.33
- AVG Volume (30 Days)
- EPRX 24.6K
- RGLS 261.9K
- Earning Date
- EPRX 02-07-2025
- RGLS 11-07-2024
- Dividend Yield
- EPRX N/A
- RGLS N/A
- EPS Growth
- EPRX N/A
- RGLS N/A
- EPS
- EPRX N/A
- RGLS N/A
- Revenue
- EPRX N/A
- RGLS N/A
- Revenue This Year
- EPRX N/A
- RGLS N/A
- Revenue Next Year
- EPRX N/A
- RGLS N/A
- P/E Ratio
- EPRX N/A
- RGLS N/A
- Revenue Growth
- EPRX N/A
- RGLS N/A
- 52 Week Low
- EPRX $2.20
- RGLS $1.08
- 52 Week High
- EPRX $4.08
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- RGLS 52.02
- Support Level
- EPRX N/A
- RGLS $1.53
- Resistance Level
- EPRX N/A
- RGLS $1.70
- Average True Range (ATR)
- EPRX 0.00
- RGLS 0.10
- MACD
- EPRX 0.00
- RGLS 0.00
- Stochastic Oscillator
- EPRX 0.00
- RGLS 35.19
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.